ZFIN ID: ZDB-PUB-180509-26
The Role of scaRNAs in Adjusting Alternative mRNA Splicing in Heart Development
Nagasawa, C., Ogren, A., Kibiryeva, N., Marshall, J., O'Brien, J.E., Kenmochi, N., Bittel, D.C.
Date: 2018
Source: Journal of cardiovascular development and disease   5(2): (Review)
Registered Authors: Kenmochi, Naoya
Keywords: alternative mRNA splicing, congenital heart defects, scaRNAs, small cajal body-associated RNAs, tetralogy of Fallot
MeSH Terms: none
PubMed: 29738469 Full text @ J Cardiovasc Dev Dis
FIGURES
ABSTRACT
Congenital heart disease (CHD) is a leading cause of death in children <1 year of age. Despite intense effort in the last 10 years, most CHDs (~70%) still have an unknown etiology. Conotruncal based defects, such as Tetralogy of Fallot (TOF), a common complex of devastating heart defects, typically requires surgical intervention in the first year of life. We reported that the noncoding transcriptome in myocardial tissue from children with TOF is characterized by significant variation in levels of expression of noncoding RNAs, and more specifically, a significant reduction in 12 small cajal body-associated RNAs (scaRNAs) in the right ventricle. scaRNAs are essential for the biochemical modification and maturation of small nuclear RNAs (spliceosomal RNAs), which in turn are critical components of the spliceosome. This is particularly important because we also documented that splicing of mRNAs that are critical for heart development was dysregulated in the heart tissue of infants with TOF. Furthermore, we went on to show, using the zebrafish model, that altering the expression of these same scaRNAs led to faulty mRNA processing and heart defects in the developing embryo. This review will examine how scaRNAs may influence spliceosome fidelity in exon retention during heart development and thus contribute to regulation of heart development.
ADDITIONAL INFORMATION No data available